FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313650177> ?p ?o ?g. }

• W4313650177 endingPage "e053927" @default.
• W4313650177 startingPage "e053927" @default.
• W4313650177 abstract "Introduction Deciding whether to stop or extend anticoagulant therapy indefinitely after completing at least 3 months of initial treatment for a first unprovoked venous thromboembolism (VTE) remains a challenge for clinicians, patients and policy makers. Guidelines suggest an indefinite duration of anticoagulant therapy in these patients, yet its benefits, harms and costs have not been formally assessed. The aim of this proposed modelling study is to assess the differences in clinical benefits, harms and costs of stopping versus continuing anticoagulant therapy indefinitely for a first unprovoked VTE. Methods and analysis We will develop a probabilistic Markov model, adopting a 1-month cycle length and a lifetime horizon, to estimate life-years, quality-adjusted life-years, costs and the incremental cost-effectiveness ratios for a simulated population of patients with a first unprovoked VTE who will receive indefinite duration of anticoagulant therapy versus a population who will not receive extended treatment after completing 3 months of initial anticoagulant therapy. The economic evaluation will adopt a third-party payer perspective relating to a Canadian publicly funded healthcare system. Estimates for the probability of relevant clinical events will be informed by systematic reviews and meta-analyses, while costs and utility values will be obtained from published Canadian sources. Stratified analyses based on sex, age and site of initial VTE will also be performed to identify subgroups of patients with a first unprovoked VTE in whom continuing anticoagulant therapy indefinitely might prove to be clinically beneficial and cost-effective over stopping treatment. We will also conduct sensitivity and scenario analyses to assess robustness of study findings to changes in individual or groups of key parameters. Ethics and dissemination Ethical approval is not applicable for this study. The results will be disseminated through presentations at relevant conferences and in a manuscript that will be submitted to a peer-reviewed journal." @default.
• W4313650177 created "2023-01-07" @default.
• W4313650177 creator A5017855915 @default.
• W4313650177 creator A5018616381 @default.
• W4313650177 creator A5020839633 @default.
• W4313650177 creator A5022700654 @default.
• W4313650177 creator A5028874004 @default.
• W4313650177 creator A5036849527 @default.
• W4313650177 creator A5051047770 @default.
• W4313650177 creator A5060373660 @default.
• W4313650177 creator A5078027320 @default.
• W4313650177 date "2023-01-01" @default.
• W4313650177 modified "2023-09-26" @default.
• W4313650177 title "Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism" @default.
• W4313650177 cites W1573523596 @default.
• W4313650177 cites W2065458063 @default.
• W4313650177 cites W2068459687 @default.
• W4313650177 cites W2075738853 @default.
• W4313650177 cites W2094559045 @default.
• W4313650177 cites W2109524995 @default.
• W4313650177 cites W2112378432 @default.
• W4313650177 cites W2112757583 @default.
• W4313650177 cites W2115787552 @default.
• W4313650177 cites W2128911553 @default.
• W4313650177 cites W2139785591 @default.
• W4313650177 cites W2144328416 @default.
• W4313650177 cites W2144714162 @default.
• W4313650177 cites W2164654252 @default.
• W4313650177 cites W2167149931 @default.
• W4313650177 cites W2169472792 @default.
• W4313650177 cites W2225937646 @default.
• W4313650177 cites W2307552230 @default.
• W4313650177 cites W2331935930 @default.
• W4313650177 cites W2568332688 @default.
• W4313650177 cites W2595086780 @default.
• W4313650177 cites W2784147326 @default.
• W4313650177 cites W2907781029 @default.
• W4313650177 cites W2964299611 @default.
• W4313650177 cites W2999034462 @default.
• W4313650177 cites W3034826720 @default.
• W4313650177 cites W3090209681 @default.
• W4313650177 cites W3188668922 @default.
• W4313650177 cites W3189636447 @default.
• W4313650177 cites W3214460883 @default.
• W4313650177 cites W4210745803 @default.
• W4313650177 cites W4234977819 @default.
• W4313650177 doi "https://doi.org/10.1136/bmjopen-2021-053927" @default.
• W4313650177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36609323" @default.
• W4313650177 hasPublicationYear "2023" @default.
• W4313650177 type Work @default.
• W4313650177 citedByCount "1" @default.
• W4313650177 countsByYear W43136501772023 @default.
• W4313650177 crossrefType "journal-article" @default.
• W4313650177 hasAuthorship W4313650177A5017855915 @default.
• W4313650177 hasAuthorship W4313650177A5018616381 @default.
• W4313650177 hasAuthorship W4313650177A5020839633 @default.
• W4313650177 hasAuthorship W4313650177A5022700654 @default.
• W4313650177 hasAuthorship W4313650177A5028874004 @default.
• W4313650177 hasAuthorship W4313650177A5036849527 @default.
• W4313650177 hasAuthorship W4313650177A5051047770 @default.
• W4313650177 hasAuthorship W4313650177A5060373660 @default.
• W4313650177 hasAuthorship W4313650177A5078027320 @default.
• W4313650177 hasBestOaLocation W43136501771 @default.
• W4313650177 hasConcept C112930515 @default.
• W4313650177 hasConcept C141071460 @default.
• W4313650177 hasConcept C142724271 @default.
• W4313650177 hasConcept C177713679 @default.
• W4313650177 hasConcept C204787440 @default.
• W4313650177 hasConcept C2778205648 @default.
• W4313650177 hasConcept C2780385302 @default.
• W4313650177 hasConcept C2780868729 @default.
• W4313650177 hasConcept C2908647359 @default.
• W4313650177 hasConcept C2991741193 @default.
• W4313650177 hasConcept C2993316766 @default.
• W4313650177 hasConcept C3019080777 @default.
• W4313650177 hasConcept C64332521 @default.
• W4313650177 hasConcept C71924100 @default.
• W4313650177 hasConcept C99454951 @default.
• W4313650177 hasConceptScore W4313650177C112930515 @default.
• W4313650177 hasConceptScore W4313650177C141071460 @default.
• W4313650177 hasConceptScore W4313650177C142724271 @default.
• W4313650177 hasConceptScore W4313650177C177713679 @default.
• W4313650177 hasConceptScore W4313650177C204787440 @default.
• W4313650177 hasConceptScore W4313650177C2778205648 @default.
• W4313650177 hasConceptScore W4313650177C2780385302 @default.
• W4313650177 hasConceptScore W4313650177C2780868729 @default.
• W4313650177 hasConceptScore W4313650177C2908647359 @default.
• W4313650177 hasConceptScore W4313650177C2991741193 @default.
• W4313650177 hasConceptScore W4313650177C2993316766 @default.
• W4313650177 hasConceptScore W4313650177C3019080777 @default.
• W4313650177 hasConceptScore W4313650177C64332521 @default.
• W4313650177 hasConceptScore W4313650177C71924100 @default.
• W4313650177 hasConceptScore W4313650177C99454951 @default.
• W4313650177 hasFunder F4320334506 @default.
• W4313650177 hasIssue "1" @default.
• W4313650177 hasLocation W43136501771 @default.
• W4313650177 hasLocation W43136501772 @default.
• W4313650177 hasLocation W43136501773 @default.

• next